Invitae said Monday that Blue Shield of California has updated its policy to cover its Personalized Cancer Monitoring (PCM) assay, a tumor tissue-informed, patient-specific technology to detect minimal residual disease in cancer patients. The policy, effective March 1, considers the test medically necessary for patients with stages I-IV cancer after surgical intervention for adjuvant [...]
Caris Life Sciences said Tuesday that it has entered a strategic research partnership with Wilmington, Delaware-based Incyte to augment precision medicine approaches for the drugmaker's oncology pipeline. Under the terms of the agreement, Incyte will use Caris' data insights and analytics capabilities to discover novel biomarkers and optimize clinical positioning strategies for two oncology [...]
Personalis said Tuesday that it is continuing a collaboration with AstraZeneca to explore the cancer sequencing firm's Next Personal molecular residual disease (MRD) test in clinical research and drug development. The two companies are evaluating the sensitivity and specificity of whole-genome-informed circulating tumor DNA testing that supports both residual disease detection and assessment of [...]
